AS Insights launch new report Aromatase Inhibitors in Breast Cancer State of the Science and Strategic Opportunities

The market for aromatase inhibitors reached US$370 million in 2001, a 27% increase over 2000. The market is expected to continue growing at a very fast pace and several windows of opportunities keep opening in that market.

In recent years, accumulating evidence has demonstrated the utility of aromatase inhibitors as therapy for postmenopausal women with estrogen receptor (ER) positive advanced breast cancer.

Aromatase inhibitors have already proved themselves superior, in major clinical trials, to existing hormonal therapies in the fight against breast cancer. These breakthrough findings are likely reinvigorate the market and spur growth rates.

Three aromatase inhibitors are currently available in the United States; the nonsteroidal inhibitors anastrozole and letrozole and the steroidal inhibitor exemestane. Another two are available on world markets, formestane and fadozole. Several products are also available in different stages of clinical trials and are expected to enter the market soon

Aromatase Inhibitors in Breast Cancer is a timely strategic consulting report from ASInsigts designed to bring the latest happenings in both clinical development and marketing arena to the attention of oncology product managers in the pharmaceutical and medical biotech industries.

The report examines the current state-of-the-science, assesses the market environment, profiles leading participants and their products and gives a helicopter view of the competitive landscape.

Report Code: 0212AS2B

Report Price:

US$485 Hard Copy (including shipping & handling) US$285 PDF Format (delivered by email)

Date Published: November 2002

Number of Pages: 20

To order - click here!